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BACKGROUND: Physical capability, a key component of healthy aging, is 
associated with cardiovascular and other risk factors across life. We investigated 
whether midlife biomarkers of heart and kidney damage capturing the 
cumulative impact of long-term adverse exposures were associated with the 
level and decline in physical capability over 9 years of follow-up, taking account 
of systemic inflammatory biomarkers and conventional cardiovascular risk 
factors.
METHODS: We used data on 1736 men and women from the oldest British 
birth cohort study with walking speed, chair rise speed, balance time, and grip 
strength assessed at ages 60 to 64 and 69 years. We tested associations between 
logged and standardized measures of cystatin C, NT-proBNP (N-terminal pro-B-
type natriuretic peptide), interleukin (IL)-6, and E-selectin at age 60 to 64 years 
with performance at age 69 years, adjusting for sex, height, and body mass 
index; then for performance at age 60 to 64 years. These biomarkers were 
mutually adjusted, and additionally adjusted for cardiovascular risk factors (pulse 
pressure, total/high density lipoprotein cholesterol, glycosylated hemoglobin), 
diabetes mellitus, cardiovascular and kidney disease, smoking status, and lifetime 
socioeconomic position.
RESULTS: Cystatin C, NT-proBNP, and IL-6 (but not E-selectin) were inversely 
associated with all outcomes, adjusted for sex, height, and body mass index. 
For example, a 1-SD increase in logged NT-proBNP was associated with 
weaker grip (−0.63 kg, 95% CI, −0.99 to −0.28); the equivalent association 
for cystatin C was −0.60 kg (95% CI, −0.94 to −0.25) and for IL-6 was −0.76 
kg (95% CI, −1.11 to −0.41). Most associations remained, albeit attenuated, 
after adjustment for previous performance and mutual adjustment of the 
biomarkers. NT-proBNP and IL-6 (but not cystatin C) were more strongly 
associated with the outcomes than many of the conventional risk factors after 
mutual adjustment.
CONCLUSIONS: Higher levels of NT-proBNP may identify those in midlife at risk 
of accelerated physical decline. Before considering the use of NT-proBNP for risk 
stratification, further research should untangle whether these associations exist 
because the biomarker is an integrated measure of cumulative exposures to 
relevant stressors across life, or whether it is marking additional risk pathways. 
Randomized trials to reduce the rate of decline in physical capability or delay 
incident disability could benefit from including middle-aged adults and adding 
NT-proBNP and IL-6 as intermediate outcomes.
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Healthy biological aging can be characterized by the following 3 domains: survival to old age, de-lay in onset of chronic disease and disability, and 
optimal physical and cognitive capability for the max-
imal period of time.1 Physical capability, the capacity 
to undertake the physical tasks of daily living, can be 
assessed using simple objective measures such as gait 
speed, chair rise speed, balance time, and grip strength. 
Poor performance on these measures has been consist-
ently shown to be associated with subsequent hospital-
ization, morbidity, disability, and mortality.2–5 Life course 
trajectories for these measures show a developmental 
stage of increased performance followed by a plateau 
and then a decline phase, although there is marked in-
terindividual variability.6
A review of potentially modifiable risk factors for 
physical capability highlighted poor lifetime socioec-
onomic conditions, obesity, and smoking, all known 
risk factors for cardiovascular disease and other 
chronic conditions.6 Similarly, higher blood pres-
sure, diabetes mellitus, and ischemic heart disease 
risk factors have also been shown to be associated 
with worse later physical capability in a number of 
cohort studies.7,8 The American Heart Association has 
recently stated that functional capacity should be pri-
oritized in older adults living with cardiovascular di-
sease, and recommended indicators such as strength 
and balance.9 Whereas most risk factors have been 
measured in mid- or later life, there is growing evi-
dence that factors from earlier life, including poorer 
growth and development, as well as adverse lifetime 
socioeconomic conditions have cumulative long-term 
negative associations with physical capability, espe-
cially muscle strength.10–14
A variety of different biological markers measured 
in the blood capture domains of current health status 
with relevance to long-term risks. For example, sys-
temic inflammatory markers are nonspecific and react 
to acute exposures such as infection, and chronically 
higher levels appear to be the consequence of process-
es or risk pathways such as obesity, which increase the 
chances of atherosclerosis. Ideally, we should examine 
organ damage using biomarkers that capture the cu-
mulative impact of long-term adverse exposures that 
may impact the level and decline in physical capability. 
Studies in midlife would be particularly useful to see 
whether those most at risk of decline could be detected 
early. There is evidence that cystatin C levels (and their 
changes with age), a potentially better measure of re-
nal dysfunction than creatinine based measures,15 are 
associated with physical capability in older adults.16,17 
NT-proBNP (N-terminal pro-B-type natriuretic peptide) 
is a marker of cardiac stress or damage that is associ-
ated with cardiovascular disease and heart failure risk 
across its entire range of measurement,18–21 and with 
physical activity,22,23 but to our knowledge has not been 
examined in relation to objective measures of physical 
capability.
Using data from the oldest British birth cohort study, 
we tested the hypothesis that markers of composite or-
gan damage/stress (cystatin C and NT-proBNP) meas-
ured at age 60 to 64 years would show associations 
with physical capability at age 69 years and the change 
in physical capability, even after taking account more 
systemic biomarkers of inflammation/vascular dysfunc-
tion (interleukin [IL]-6, E-selectin), and cardiometabolic 
and lifetime sociobehavioral risk factors. We further hy-
pothesized that these measures of specific organ dam-
age/stress could show stronger associations than those 
reflecting less specific systemic exposures.
METHODS
The Medical Research Council (MRC) NSHD (National Survey 
of Health and Development) is a sample of 5362 males and 
females born in England, Scotland, and Wales in 1 week in 
March 1946 and followed up since. The 24th data collec-
tion was conducted between 2014 and 2015 when study 
members were aged 68 to 69 years.24 At age 69 years, after 
a postal questionnaire at age 68 years, study members still 
alive and with a known current address in mainland Britain 
(n=2698) were invited to have a home visit; 2149 (79.7%) 
completed a visit and a further 55 (2.0%) completed a postal 
questionnaire instead. Of the original cohort, 1026 (19.1%) 
had died, 578 (10.8%) were living abroad, 22 (0.4%) asked 
for their participation to be restricted to postal contacts, 621 
Clinical Perspective
What Is New?
• Lower levels of NT-proBNP (N-terminal pro-B-type 
natriuretic peptide) and interleukin-6 in mid-
dle-aged adults were independently associated 
with better physical capability (a key component of 
healthy aging) up to 9 years later.
• Such associations were meaningfully stronger than 
those observed for conventional risk markers in-
cluding lipids, blood pressure, and glycemia and 
were not explained by the onset of cardiovascular 
and kidney disease or diabetes mellitus.
What Are the Clinical Implications?
• Elevated NT-proBNP and interleukin-6 in midlife 
could help identify (and thereby target) individuals 
set to have poor physical capability as they age.
• Such findings may relate in part to such biomarkers 
capturing early end-organ damage, or cumulative 
stressor pathways that lead to physical decline.
• Future trials targeting improvements in physical ca-
pability should include middle-aged as well as older 
adults and use measurements of cardio-renal bio-
markers as intermediate outcomes.
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(11.6%) had previously withdrawn from the study, and 417 
(7.8%) had been lost to follow-up. Ethical approval for the 
most recent visit was given by Queen Square Research Ethics 
Committee (14/LO/1073) and Scotland A Research Ethics 
Committee (14/SS/1009). Written informed consent was pro-
vided by participants for each visit.
Physical Capability Outcomes
At age 69 years, physical capability was assessed using 4 
objective measures: grip strength, chair rise speed, walking 
speed, and standing balance time. Trained nurses conducted 
these tests using standardized protocols as summarized here. 
Grip strength (kilograms) was measured isometrically using a 
Jamar Plus+ Digital Hand dynamometer. Two values were re-
corded for each hand while the participant was seated, and 
the highest value achieved was used in analyses. Chair rise 
time was measured, using a stopwatch, as the time taken 
to rise from a sitting to a standing position with straight 
back and legs and then sit down again 10 complete times 
as fast as possible. If the participant began the test but was 
unable to perform all 10 rises (n=26), the number of rises 
completed was recorded. To take account of differences in 
the number of rises completed and for high scores to indicate 
good performance, chair rise speed (stands per minute) was 
calculated by dividing the number of completed rises by the 
time taken (in minutes). Walking speed (meters per second) 
was measured by recording the time taken in seconds (to 
the nearest millisecond) to walk 2.44 m (8 feet) at a normal 
pace from a standing start and then dividing 2.44 m by this 
time. Walking aids were permitted for this test (n=88), and 
participants were asked to complete it twice with the fastest 
of the 2 speeds achieved used in analyses. Standing balance 
time was measured, using a stopwatch, as the longest time, 
up to a maximum of 30 seconds, for which participants could 
maintain a 1-legged stance in a standard position with their 
eyes closed. Balance times were skewed and so were trans-
formed by natural logarithm for analyses after adding 1 to 
avoid zero values. For each of the 4 tests, nurses recorded 
whether a study participant was unable or unwilling to per-
form the test and the reason for this (eg, health reasons, 
technical problems).
Physical performance tests were also conducted at age 
60 to 64 years. These were the same measures as at age 69 
years, except that the timed up and go test had been used 
instead of the walking speed test. To measure timed up and 
go, the time taken for participants to rise from an armless 
chair, walk 3 m, turn around, return to the chair, and sit down 
was recorded. The test was performed once at a normal pace, 
and walking aids were permitted (n=24). Timed up and go 
speed (meters/second) was calculated by dividing the distance 
walked (6 m) by the time taken (seconds).
Markers of Composite Organ Damage 
and Inflammation at Age 60 to 64 Years
Fasting overnight blood samples were taken by nurses, ini-
tially processed at clinical research facility laboratories, and 
stored at −80°C. Frozen aliquots were transferred monthly to 
the MRC Human Nutrition Research laboratory in Cambridge. 
Analyses of cystatin C, NT-proBNP, E-selectin, and IL-6 were 
subsequently undertaken in a central laboratory (Table I in the 
online-only Data Supplement). We derived a cystatin-based 
estimated glomerular filtration rate, calculated using the 
chronic kidney disease Epidemiology Collaboration formulas 
dating from 2012.25
Covariables
We identified the following covariables (at age 60–64 years 
unless otherwise specified) that have been shown to be re-
lated to physical capability and the novel biomarkers and that 
might therefore confound the analyses. The first set of covari-
ables included sex and body size (height and body mass index 
[BMI]).6,21,26 The second set of covariables included measures 
of disease status (prevalent cardiovascular disease, diabetes 
mellitus, or kidney disease), cardiovascular risk (pulse pressure, 
total:high-density lipoprotein cholesterol ratio, hemoglobin 
A1c, and smoking), and lifetime socioeconomic position.6,7,11 
Cardiovascular disease was based on self-reports of doctor-
diagnosed myocardial infarction, stroke, angina, coronary 
artery bypass graft, or angioplasty procedures. Diabetes mel-
litus was based on self-reports of doctor-diagnosed diabetes 
mellitus that have been validated against general practitioner 
records. Chronic kidney disease was defined as cystatin-based 
estimated glomerular filtration rate <60 mL/min/1.73 m2 
based on agreed criteria.27 We distinguished smokers from 
non- or ex-smokers. Pulse pressure (mm Hg) was calculated 
by taking the second of 2 measures of diastolic blood pres-
sure from the second of 2 measures of systolic blood pressure. 
We used pulse pressure, rather than systolic blood pressure, 
as it acts as “an indirect index of large artery stiffness”28 and 
hence may be a better measure of cumulative damage and 
arterial aging, though we also examined the impact of using 
systolic blood pressure (see Additional Analyses). Plasma lipids 
(total cholesterol, triglycerides, and high-density lipoprotein 
cholesterol) were performed by modification of the standard 
Lipid Research Clinics Protocol using enzymatic reagents for 
lipid determination and the total:high-density lipoprotein 
cholesterol ratio derived. Socioeconomic position was based 
on father’s occupational class in childhood (at age 11 years 
or at 4 or 15 years if missing at 11 years) and own occupa-
tional class at age 53 years (or at earlier ages if missing at age 
53 years), classified by the Registrar General’s classification 
into 6 social classes (I=highest and V=lowest). A third set of 
covariables, only included in additional analyses, were anx-
iety and depression using the conventional cut point of 5 or 
more symptoms over the previous 4 weeks from the 28-item 
General Health Questionnaire (GHQ28), self-reported bodily 
pain over the previous 4 weeks on a 6-point scale (none, very 
mild, mild, moderate, severe, very severe), use of statin med-
ication (yes/no), use of antihypertensive medication (yes/no), 
carotid intima thickness measured (cIMT) in a subsample (see 
details elsewhere29), and self-reported doctor-diagnosed car-
diovascular disease (CVD), kidney disease, or diabetes mellitus 
at age 69 years.
Statistical Analysis
The mean level and SD or median and interquartile range of 
all the physical capability outcomes and the biomarkers of 
organ damage/stress or inflammation were derived for the 
total sample and separately for men and women using their 
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original units of measurement. For subsequent analyses, the 
continuous biomarkers were transformed using the natural 
logarithm to reduce skewness and then standardized (to have 
a mean of 0 and a SD of 1) for comparative purposes. In pre-
liminary analyses, we tested for nonlinearity between each 
standardized biomarker score at age 60 to 64 years and each 
outcome at age 69 years by (1) testing a quadratic function, 
(2) including the biomarkers split by quintiles and compar-
ing associations between models that included the 5 groups 
as continuous or categorical exposures, and (3) using frac-
tional polynomials.30 Using a nonlinear function did not im-
prove the model fit except for the relationship between IL-6 
and standing balance where there was some evidence that 
adding a quadratic term improved the fit. However, because 
this did not change the overall findings, we present the main 
tables assuming linear relationships throughout. We tested, a 
priori, whether the relationships between the main exposures 
and each outcome differed by sex by adding exposure by sex 
interactions.
Modeling Strategy
We investigated the associations between cystatin C, 
NT-proBNP, IL-6, and E-selectin at age 60 to 64 years with 
each physical capability outcome at age 69 years, adjusting 
first for sex and then additionally for height and BMI. We then 
additionally adjusted for the same performance measure at 
age 60 to 64 years (except for walking speed, where we used 
timed up and go speed) to assess whether the novel biomark-
ers were associated with decline in performance between 
ages 60 to 64 years and 69 years. Finally, we further adjusted 
for disease status, conventional cardiovascular risk factors, 
and lifetime socioeconomic position for those biomarkers 
that remained associated with the outcomes at the 5% level 
to see whether the novel biomarkers were still associated con-
ditional on these measures.
Additional Analyses
We tested the cross-sectional associations of the novel bio-
markers and the other covariables with physical capability 
outcomes at age 60 to 64 years in those who had repeat 
performance measures at age 69 years, and compared the 
estimates with the estimates at age 69 years to see whether 
they differed.
We reran the final regression models including a biomarker 
and disease status interaction term to investigate whether the 
associations were similar between those with and without 
disease. We also reran these regression models excluding 
those with CVD, diabetes mellitus, or kidney disease. In this 
sample, we additionally adjusted for new-onset CVD, kidney 
disease, or diabetes mellitus at age 69 years to see whether 
this explained associations between the biomarkers and 
outcomes. We repeated the main analyses including those 
unable to do the physical capability tests because of health 
problems. We did this by giving a value equal to the midpoint 
of the lowest sex-specific fifth (n=12 for grip strength, 44 for 
chair rise speed, and 14 for walking speed) and a value of 
zero for standing balance time (n=55). To check whether our 
findings changed, we also reran the multivariable analyses 4 
more times: using systolic blood pressure rather than pulse 
pressure, additionally adjusting for bodily pain and caseness 
on the GHQ28, additionally adjusting for statin and antihy-
pertensive medications, and taking account of subclinical 
vascular disease in a subsample by additionally adjusting for 
cIMT. STATA14 was used for all analyses.
Data used in this publication are available to bona fide 
researchers on request to the NSHD Data Sharing Committee 
via a standard application procedure; details can be found 
elsewhere.31
RESULTS
The maximum sample for analysis was 1736 individu-
als with ≥1 measure of physical capability at age 69 
years and measures of cystatin C or NT-proBNP and 
both height and BMI at age 60 to 64 years. Table 1 
shows the descriptive characteristics for the total sam-
ple and for men and women separately. Men had 
stronger grip, longer balance times, and faster chair 
rise and walking speeds at ages 60 to 64 years and 69 
years. At age 60 to 64 years, levels of cystatin C and 
E-selectin were higher in men but levels of NT-proBNP 
were higher in women; there was no difference in IL-6 
levels. Levels of pulse pressure and total/high-density 
lipoprotein cholesterol ratio were higher in men; there 
was no difference in levels of hemoglobin A1c. Men 
were taller, more likely to have CVD, diabetes mellitus, 
or kidney disease, and more like to have a higher adult 
social class; there were no sex differences in BMI or 
childhood social class.
Higher levels of all 4 biomarkers were associated 
with weaker grip strength, shorter balance times, and 
slower chair rise and walking speeds at age 69 years 
in sex-adjusted models (Table 2, model 1). The asso-
ciation between NT-proBNP and chair rise speed was 
only apparent in men (P value for interaction=0.002). 
After adjusting for height and BMI, cystatin C, NT-proB-
NP, and IL-6 remained inversely associated with all the 
outcomes, and E-selectin remained inversely associated 
with grip strength and chair rise speed (model 2). On 
further adjustment for the equivalent performance test 
at age 60 to 64 years, these associations were attenu-
ated: all biomarkers remained inversely associated with 
grip strength, all but E-selectin remained inversely asso-
ciated with standing balance time and walking speed, 
and NT-proBNP and IL-6 remained inversely associated 
with chair rise speed (model 3).
Correlations between the novel biomarkers were all 
modest and <0.2. Mutually adjusting for all 4 biomark-
ers in the same model and adjusting for sex, height, and 
BMI showed that E-selectin was not associated inde-
pendently with any of the physical capability outcomes 
(Table 3) and was not considered further in the anal-
ysis. Most of the other pre-existing associations were 
modestly attenuated, although there were no longer 
associations between cystatin C and chair stands and 
IL-6 and standing balance.
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In the sample with complete data on covariables, 
higher levels of NT-proBNP continued to be strongly as-
sociated with all the outcomes (except chair rise speed 
in women) after taking account of disease status and 
conventional cardiovascular risk factors (Figures 1–4, Ta-
ble II in the online-only Data Supplement). Higher levels 
of IL-6 remained associated with weaker grip strength 
and slower chair rise and walking speeds, but were no 
longer associated with standing balance time. Levels 
of cystatin C were the most strongly attenuated in the 
fully adjusted model and were no longer independently 
associated with any of the outcomes. The inverse asso-
ciation between NT-proBNP and chair rise speed contin-
ued to be stronger in men rather than women.
In these final models, women continued to have 
weaker grip strength, slower chair rise speed, and 
shorter balance times. Those of heavier BMI had slow-
er chair rise and walking speeds and shorter balance 
times, and those of taller stature had stronger grip but 
slower chair rise speed. There were few associations 
of disease status or cardiovascular risk factors with the 
physical capability outcomes in the fully adjusted mod-
els. In these models, participants with CVD, diabetes 
mellitus, or kidney disease had weaker grip strength 
and slower chair rise speed. Smokers had slower chair 
rise and walking speeds. Those with higher levels of 
hemoglobin A1c had shorter balance times, and those 
of lower adult socioeconomic position had slower 
walking speed.
Additional Analyses
The estimates for the cross-sectional associations be-
tween the novel biomarkers and the physical capability 
outcomes at age 60 to 64 years were smaller or similar 
for NT-proBNP and E-selectin but larger or similar for 
cystatin C and IL-6 (except for grip strength) than the 
estimates with the outcomes at age 69 years (Table III in 
the online-only Data Supplement).
The estimates for model 2 (shown in Figures  1–4 
and Table II in the online-only Data Supplement) were 
similar when excluding the sample with CVD, diabetes 
mellitus, or kidney disease (data available on demand). 
Within this sample, adjusting for CVD, diabetes melli-
tus, or kidney disease at age 69 years did not attenuate 
the estimates for the biomarkers (Table IV in the online-
only Data Supplement). We found no evidence of an 
interaction between disease status and the novel bio-
markers on grip strength, chair rise, or walking speeds. 
Nor did our findings change when substituting systolic 
blood pressure for pulse pressure, or including GHQ28 
caseness and bodily pain (Table V in the online-only 
Data Supplement) or statin and antihypertensive med-
ication (Table VI in the online-only Data Supplement). 
In the subsample with cIMT, estimates for the biomark-
ers hardly changed when cIMT was added to the final 
models (data available on demand).
The overall findings remained the same when includ-
ing those unable to do the tests for health reasons. Es-
timates in the main analyses (Table 2 and Figures 1–4) 
generally became very slightly bigger, with the associa-
tion between NT-proBNP and chair rise speed strength-
ened the most.
DISCUSSION
In a large population-based study, higher levels of NT-
proBNP, a marker of cardiac damage or stress, and to 
a slightly lesser extent IL-6, a measure of systemic in-
flammation, were inversely associated with subsequent 
levels of grip strength, standing balance, chair rise speed 
(men only), and walking speed over a 6-year follow-up 
during the seventh decade of life. Both these biomark-
ers were associated with these outcomes after adjusting 
for the equivalent outcome at baseline, suggesting that 
they were related to a faster decline in performance. 
Notably, the associations per 1-SD change in log NT-
proBNP with most of these outcomes were generally 
much stronger than associations with similar increments 
in lipids, blood pressure, or glycemia and 5 times as 
strong as smoking status. The magnitude of effect of 
a 1-SD increase in log NT-proBNP (0.63 kg grip strength 
in the adjusted model) was equivalent to a 1.17-year 
decrease in grip strength (average decline, 0.54 kg per 
year). Higher levels of cystatin C were also associated 
with the decline in grip strength, chair stands, and walk-
ing speed; however, cystatin C was not independently 
related to these outcomes once disease status and con-
ventional cardiovascular risk factors were accounted for. 
E-selectin, considered a marker of vascular function, did 
not add value as it was not associated with decline nor 
Figure 1. Estimates from a linear regression model showing the mean 
difference in grip strength (kg) by mutually adjusted natural logged 
novel and conventional risk factors (also adjusted for sex and child-
hood and lifetime socioeconomic position).  
See also Table II in the online-only Data Supplement. BMI indicates body mass 
index; CVD, cardiovascular disease; HbA1c, hemoglobin A1c; HDL, high-den-
sity lipoprotein; IL, interleukin; ln, natural logarithm; NT-proBNP, N-terminal 
pro-B-type natriuretic peptide; and sd, 1 standard deviation.
D
ow
nloaded from
 http://ahajournals.org by on August 9, 2019
Kuh et al Midlife NT-proBNP and Physical Capability
Circulation. 2019;139:1988–1999. DOI: 10.1161/CIRCULATIONAHA.118.037332 April 23, 2019 1993
ORIGINAL RESEARCH 
ARTICLE
independently associated with the outcomes once the 
associations between the other novel biomarkers and 
physical capability outcomes were taken into account.
Our results are consistent with some of the previous 
literature on cystatin C, IL-6, and NT-proBNP, although 
there is far less evidence for NT-proBNP. Cystatin C is 
strongly associated with both cardiovascular and non-
cardiovascular mortality.32 Elevated cystatin C, but not 
creatinine-based measures of renal function, was also 
associated with frailty and slower walking speed.33 The 
only study that has looked at functional trajectories was 
from the Cardiovascular Health Study and showed that 
cystatin and IL-6 were both associated with decline in-
dependent of other biomarkers for gait speed and grip 
strength but only cystatin C was associated with worsen-
ing cognitive function.16 Similar cross-sectional associa-
tions were seen in the InChianti study between IL-6 and 
grip strength, walk speed, balance, and chair stands.34 
These cross-sectional associations were also seen in the 
MacArthur Studies of Successful Aging, but no associa-
tions were found for IL-6 prospectively, though higher 
IL-6 was associated with increased mortality.35 The 
Health ABC study also found inverse associations with 
IL-6 and grip strength and 400-m walk time but as part 
of a factor-analysis derived component with C-reactive 
protein and plasminogen activator inhibitor-1.36 These 
findings broadly implicate low-grade inflammation as 
relevant to a decline in physical capability.
Importantly, the absolute levels of NT-proBNP we 
observe in the NSHD fall generally within the expected 
range, broadly consistent with many other general co-
hort studies of similar age.18 Although NT-proBNP is 
well recognized as a predictor of CVD events and CVD 
mortality as seen in recent meta-analyses, including 
work co-led from some of our own group,18–20 very 
little evidence relates to its role in relation to physical 
capacity. In longitudinal studies of the oldest old, el-
evated NT-proBNP predicted worsening performance 
on activities of daily living and cognitive decline (Lei-
den 85+ study),37 and left ventricular mass predicted 
functional decline in terms of activities of daily living 
(Jerusalem longitudinal study).38 Additionally, higher 
NT-proBNP was associated with incident disability.39 
NT-proBNP is an important biomarker in the diagnosis 
of heart failure,40 and the upper limit of normal for NT-
proBNP is 125 pg/mL. However, low-grade elevation 
Figure 2. Estimates from a linear regression model showing the mean 
difference in chair rise speed (stands per minute) by mutually adjusted 
natural logged novel and conventional risk factors (also adjusted for 
sex and childhood and lifetime socioeconomic position).  
Estimate for NT-proBNP is for men. See also Table II in the online-only Data 
Supplement. BMI indicates body mass index; CVD, cardiovascular disease; 
HbA1c, hemoglobin A1c; HDL, high-density lipoprotein; IL, interleukin; ln, 
natural logarithm; NT-proBNP, N-terminal pro-B-type natriuretic peptide; and 
sd, 1 standard deviation.
Figure 3. Estimates from a linear regression model showing the mean 
difference in standing balance time (natural logarithm, seconds) by mu-
tually adjusted natural logged novel and conventional risk factors (also 
adjusted for sex and childhood and lifetime socioeconomic position).  
See also Table II in the online-only Data Supplement. BMI indicates body mass 
index; CVD, cardiovascular disease; HbA1c, hemoglobin A1c; HDL, high-den-
sity lipoprotein; IL, interleukin; ln, natual logarithm; NT-proBNP, N-terminal 
pro-B-type natriuretic peptide; and sd, 1 standard deviation.
Figure 4. Estimates from a linear regression model showing the mean 
difference in walking speed (meters per second) by mutually adjusted 
natural logged novel and conventional risk factors (also adjusted for 
sex and childhood and lifetime socioeconomic position).  
See also Table II in the online-only Data Supplement. BMI indicates body mass 
index; CVD, cardiovascular disease; HbA1c, hemoglobin A1c; HDL, high-den-
sity lipoprotein; IL, interleukin; ln, natural logarithm; NT-proBNP, N-terminal 
pro-B-type natriuretic peptide; and sd, 1 standard deviation.
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Table 1. Characteristics of the Sample of 1736 (837 Men and 899 Women) Participants in NSHD With ≥1 Measure of Physical Capability at Age 69 
Years and a Measure of Cystatin C or NT-proBNP, and Height and BMI at Age 60 to 64 Years
Physical capability at 69 y
No. (Men/
Women)
Total sample Men Women
Mean (SD) or 
Median (Q1, Q3)
Mean (SD) or 
Median (Q1, Q3)
Mean (SD) or 
Median (Q1, Q3)
Grip strength, kg 1715 (833/882) 32.0 (10.8) 40.4 (8.3) 24.1 (5.8)
Chair rise speed, stands per minute 1557 (745/812) 27.1 (8.5) 27.7 (8.6) 26.5 (8.4)
Walking speed, m/s 1621 (769/852) 1.09 (0.30) 1.11 (0.31) 1.07 (0.29)
Standing balance, s 1635 (798/837) 3.01 (2.00, 4.80) 3.10 (2.07, 5.15) 2.97 (1.94, 4.44)
Covariables at 60–64 y
  Grip strength, kg 1625* (797/828) 35.8 (13.5) 45.5 (11.4) 26.4 (7.3)
  Chair rise speed, stands per minute 1496* (716/780) 26.3 (7.4) 26.9 (7.3) 25.7 (7.5)
  TUG speed, m/s 1527* (719/808) 0.70 (0.17) 0.72 (0.17) 0.69 (0.17)
  Standing balance, s 1601* (780/821) 3.57 (2.47, 5.34) 3.84 (2.59, 5.76) 3.40 (2.37, 4.88)
  Cystatin C, mg/L 1734 (836/898) 0.81 (0.73, 0.89) 0.82 (0.74, 0.90) 0.80 (0.72, 0.88)
  NT-proBNP, pg/mL 1736 (837/899) 54.9 (30.8, 93.0) 43.8 (23.6, 76.0) 64.0 (40.0, 106.0)
  E-selectin, ng/mL 1733 (835/898) 36.2 (26.2, 47.6) 37.8 (27.7, 48.8) 34.6 (25.4, 46.4)
  IL-6, pg/mL 1733 (836/897) 1.9 (1.3, 3.0) 1.9 (1.3, 3.1) 1.9 (1.3, 2.9)
  Pulse pressure, mm Hg 1732 (837/895) 57.0 (49.0, 65.0) 58.0(51.0, 67.0) 55.0 (48.0, 63.0)
  Total cholesterol/HDL cholesterol, ratio 1731 (835/896) 3.6 (3.0, 4.3) 3.7 (3.1, 4.5) 3.5 (2.9, 4.0)
  HbA1c, % 1663 (797/866) 5.7 (5.5, 6.0) 5.7 (5.5, 6.0) 5.7 (5.5, 6.0)
  Height, cm 1736 (837/899) 167.5 (161.3, 175.1) 175.2 (170.8, 179.3) 161.8 (157.8, 165.6)
  BMI, kg/m2 1736 (837/899) 27.1 (24.5, 30.4) 27.4 (24.9, 30.0) 26.9 (24.2, 30.7)
CVD, diabetes mellitus, or kidney disease, % 1546 (750/796) 13.5 16.5 11.11
Smoker, % 1707 (821/886) 10.8 10.5 11.2
Childhood social class 1648 (802/846)    
  I, % 135 8.2 9.1 7.3
  II, % 368 22.3 21.6 23.0
  III NM, % 301 18.3 18.7 17.8
  III M, % 488 29.6 29.9 29.3
  IV, % 276 16.7 15.6 17.8
  V, % 80 4.8 5.1 4.6
Adult social class 1730 (833/897)    
  I, % 136 7.9 14.6 1.6
  II, % 719 41.6 43.3 39.9
  III NM, % 415 24.0 10.3 36.7
  III M, % 246 14.2 22.8 6.2
  IV, % 161 9.3 7.0 11.5
  V, % 53 3.1 1.9 4.1
Variables used in additional analyses     
  GHQ28, 5+ score, % 1698 (823/875) 16.8 12.5 20.8
  Bodily pain, % 1609 (770/839)    
  None, %  32.3 38.6 26.6
  Very mild, %  25.7 22.7 28.5
  Mild, %  18.8 18.4 19.1
  Moderate, %  16.8 14.7 18.8
  Severe, %  5.5 5.3 5.7
  Very severe, %  0.8 0.3 1.3
New-onset CVD, diabetes mellitus, or kidney disease, age 69 y, % 1330† (623/707) 10.0 11.2 8.9
BMI indicates body mass index; CVD, cardiovascular disease; GHQ28, 28-item General Health Questionnaire; HbA1c, hemoglobin A1c; HDL, high-density 
lipoprotein; M, manual; NM, nonmanual; NSHD, National Survey of Health and Development; NT-proBNP, N-terminal pro-B-type natriuretic peptide; Q1, quartile 1; 
Q3, quartile 3; and TUG, timed up and go.
*Number refers to participants whose performance was assessed at age 60–64 years and age 69 years.
†Excludes 209 with these diseases at age 60–64 years and 7 with unknown disease status at age 69 years.
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in NT-proBNP is related to future risk of heart failure.18 
As such, low-grade elevation in NT-proBNP might be 
expected to be an early marker of end organ damage 
that is an antecedent of decline in physical capability. 
Our present study meaningfully extends existing ob-
servations and identifies the potential for future clini-
cal use of NT-proBNP in the identification of individuals 
at risk of poor physical capability in later life.
Table 2. Estimates From Linear Regression Models Showing Measures of Physical Performance at Age 69 Years by 1 SD of Natural Logged Novel 
Biomarker, Sex-Adjusted, Then Additionally Adjusted for Height and BMI, Then Additionally Adjusted for the Same Performance Test at Age 60 to 
64 Years
Sex-Adjusted
(Model 1)
Sex-, Height-, BMI-Adjusted
(Model 2)
+ Adjusted for Performance
at Age 60-64 Years
(Model 3)
Reg. Coeff. (95% CI)
P  
Value Reg. Coeff. (95% CI)
P 
Value Reg. Coeff. (95% CI)
P 
Value
Grip strength, kg
  Cystatin C, ln (SD; n=1623) −0.48 (−0.83 to −0.13) .008 −0.60 (−0.94 to −0.25) .001 −0.34 (−0.65 to −0.037) .028
  NT-proBNP, ln (SD; n=1625) −0.46 (−0.82 to −0.088) .015 −0.63 (−0.99 to −0.28) <0.001 −0.52 (−0.83 to −0.20) .001
  E-selectin, ln (SD; n=1622) −0.42 (−0.77 to −0.076) .017 −0.36 (−0.70 to −0.015) .04 −0.32 (−0.62 to −0.014) .04
  IL-6, ln (SD; n=1622) −0.83 (−1.18 to −0.47) <0.001 −0.76 (−1.11 to −0.41) <0.001 −0.38 (−0.69 to −0.066) .018
Chair rise speed, stands per minute
  Cystatin C, ln (SD; n=1494) −0.77 (−1.21 to −0.32) .001 −0.45 (−0.90 to 0.0039) .05 −0.19 (−0.59.0.21) .3
  NT-proBNP, ln (SD; n=1496) −1.48 (−2.10 to −0.86) <0.001 −1.37 (−1.99 to −0.35) .001 −0.95 (−1.49 to −0.41) .001
  NT-proBNP×sex 1.48 (0.53 to 2.44) .002 1.31 (0.37 to 2.25) .006 1.01 (0.18 to 1.85) .017
  E-selectin, ln (SD; n=1493) −0.76 (−1.20 to −0.33) .001 −0.52 (−0.96 to −0.076) .022 −0.26 (−0.64 to 0.14) .2
  IL-6, ln (SD; n=1493) −1.21 (−1.64 to −0.77) <0.001 −0.99 (−1.43 to −0.55) <0.001 −0.60 (−0.99 to −0 to 21) .003
Standing balance, ln sec
  Cystatin C, ln (SD; n=1599) −0.066 (−0.095 to −0.037) <0.001 −0.048 (−0.077 to −0.019) .001 −0.32 (−0.060 to −0.003) .029
  NT-proBNP, ln (SD; n=1599) −0.045 (−0.075 to −0.014) .004 −0.046 (−0.076 to −0.016) .003 −0.036 (−0.065 to −0.006) .018
  E-selectin, ln (SD; n=1599) −0.040 (−0.068 to −0.012) .005 −0.019 (−0.048 to 0.009) .2 −0.021 (−0.049 to 0.006) .1
  IL-6, ln (SD; n=1598) −0.054 (−0.083 to −0.025) <0.001 −0.033 (−0.063 to −0.004) .024 −0.028 (−0.056 to 0.000) .05
Walking speed, m/s
  Cystatin C, ln (SD; n=1525) −0.038 (−0.054 to −0.023) <0.001 −0.027 (−0.043 to −0.012) .001 −0.020 (−0.035 to −0.005) .008
  NT-proBNP, ln (SD; n=1527) −0.037 (−0.054 to −0.021) <0.001 −0.039 (−0.054 to −0.022) <0.001 −0.032 (−0.048 to −0.017) <0.001
  E-selectin, ln (SD; n=1524) −0.025 (−0.040 to −0.010) .002 −0.011 (−0.027 to 0.004) .1 −0.005 (−0.020 to 0.010) .5
  IL-6, ln (SD; n=1524) −0.048 (−0.063 to −0.032) <0.001 −0.035 (−0.050 to −0.020) <0.001 −0.029 (−0.043 to −0.014) <0.001
BMI indicates body mass index; IL, interleukin; ln, natural logarithm; ln sec., natural logarithm seconds; NT-proBNP, N-terminal pro-B-type natriuretic peptide; and 
Reg. Coeff., regression coefficient.
Table 3. Estimates From Linear Regression Models Showing Measures of Physical Performance at Age 69 Years by Natural Logged Novel 
Biomarkers at Age 60 to 64 Years Mutually Adjusted and Additionally Adjusted for Sex and Standardized Height and BMI at Age 60 to 64 Years
Grip Strength, kg  
(n=1710)
Chair Rise Speed, per Minute 
(n=1552)
Standing Balance, ln sec 
(n=1630)
Walking Speed, m/s 
(n=1616)
Reg. Coeff.  
(95% CI) P Value
Reg. Coeff.  
(95% CI) P Value
Reg. Coeff.  
(95% CI) P Value
Reg. Coeff.  
(95% CI) P Value
Cystatin C, ln (SD) −0.44  
(−0.79 to −0.01)
.014 −0.35  
(−0.80 to 0.097)
.1 −0.037  
(−0.066 to −0.007)
.02 −0.019  
(−0.034 to −0.004)
.01
NT-proBNP, ln (SD) −0.53  
(−0.88 to −0.17)
.004 −1.18  
(−1.77 to −0.59)
<0.001 −0.036  
(−0.067 to −0.006)
.02 −0.030  
(−0.046 to −0.015)
<0.001
NT-proBNP×sex n/a  1.16  
(0.24 to 2.08)
.014 n/a  n/a  
E-selectin, ln (SD) −0.22  
(−0.56 to  0.11)
.2 −0.40  
(−0.83 to 0.034)
.07 −0.015  
(−0.044 to 0.013)
.3 −0.0066  
(−0.021 to 0.008)
.4
IL-6, ln (SD) −0.76  
(−1.11 to −0.41)
<0.001 −0.86  
(−1.30 to  0.43)
<0.001 −0.023  
(−0.053 to 0.006)
.1 −0.029  
(−0.044 to −0.014)
<0.001
BMI indicates body mass index; IL, interleukin; ln, natural logarithm; ln sec, natural logarithm seconds; n/a, not applicable; NT-proBNP, N-terminal pro-B-type 
natriuretic peptide; and Reg. Coeff., regression coefficient.
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We had hypothesized that biomarkers that cap-
tured cumulative adverse exposures through end-organ 
damage/stress (eg, NT-proBNP, cystatin C) might have 
stronger associations than nonspecific generic inflam-
matory measures. We did indeed find that the former 
were strongly and consistently associated, but so was 
IL-6, an acute phase cytokine that has been linked to 
greater CVD and non-CVD risks, with emerging genetic 
evidence for links being causal for CVD.41 Comparing 
the estimates for NT-proBNP and IL-6 suggests that the 
associations were similar for grip strength and walking 
speed but that the associations between NT-proBNP and 
standing balance and chair rise speed (in men) were 
stronger. Recently, in the Cardiovascular Health Study, a 
biomarker index that included both these two biomark-
ers was associated with mortality in older adults.42
Conceptually there are several reasons these types of 
markers may be predictive of physical capability. First, 
their elevations may be secondary to cardiovascular 
and other chronic diseases (both clinical and subclini-
cal) and their respective risk factors, which themselves 
have an adverse effect on capability.6,7 This may explain 
why the effects of cystatin C in the final model were 
attenuated. In our final multivariable models, only grip 
strength was predicted by disease status at age 60 to 
64 years. Disease status at age 69 years in those with 
no disease at age 60 to 64 years was also associated 
with grip strength; however, adjusting for new-onset 
disease had little effect on the biomarker estimates, 
suggesting the associations we report were not sim-
ply secondary to chronic disease. Second, they share 
common upstream risk factors such as adverse child-
hood circumstances that impact on neurodevelopmen-
tal pathways. Third, they may act beyond simple proxy 
markers of damage/stress but may have adverse effects 
or associations themselves particularly on or with neu-
rological function. NT-proBNP has been associated with 
worse cognition and incident dementia, and it has been 
suggested that this may operate through a role in regu-
lating the blood-brain barrier, neurotransmission, and 
neuroinflammation.43,44 Paradoxically, there is evidence 
that elevated NT-proBNP is associated with reduced risk 
of type 2 diabetes mellitus,45 which should be bene-
ficial in terms of neurological damage. That said, NT-
proBNP is more likely a downstream marker of cardiac 
or vascular stress and, given its hemodynamic actions, 
B-type natriuretic peptide per se is considered a protec-
tive molecule. Fourth, as these measures are captured 
in a continuous fashion and have been shown to add 
predictive value for CVD outcomes, they may add use-
ful insights into individuals’ CVD health status and, 
consequently, their physical capability. Elevated cystatin 
C has inconsistent association with cognitive impair-
ment, white matter hyperintensities, and dementia, 
with some studies showing a positive association,46,47 
an inverse association,48 or a U-shaped pattern.49 IL-6 
reflects low-grade systemic inflammation (which in turn 
derives from a range of other risk factors such as obe-
sity and smoking), and there is evidence that it is on a 
common causal cytokine pathway for CVD and other 
poor health outcomes in old age.41 We have no good 
explanation for the observed sex interaction with NT-
proBNP and chair rise speed and, as this was not stated 
a priori, it may represent a type I error.
Strengths and Limitations
This is one of the largest population-based studies that 
has been able to examine a variety of biomarkers in 
relation to subsequent objective measures of physical 
capability and adjust for a wide range of potential con-
founders. We were able to test for linear and nonlinear 
function as well as sex interactions. Our findings were 
generally consistent both in cross-sectional and longitu-
dinal associations, suggesting that there is no major col-
lider bias attributable to survivorship. Another strength 
of this study is that the sample is in middle age and the 
findings suggest that early detection of those at risk 
of poor physical capability may be possible. Most other 
reports of NT-proBNP include much older populations. 
However, with only 2 serial measures of physical capa-
bility, we were limited in our ability to assess change. 
Inevitably there were missing data, but including those 
unable to be assessed for health reasons did not alter 
our findings. We acknowledge the limitation that we 
did not fully adjust for vascular disease, but accounting 
for cIMT as a surrogate for subclinical vascular disease 
in a subsample made no difference to our findings. Our 
final models may have in some cases underestimated 
the biomarker strength of association as a result of po-
tential overadjustment; both novel and conventional 
risk factors may have bidirectional associations (eg, 
blood pressure effect on renal function, which in turn 
can modify blood pressure; early cardiac dysfunction 
may impact on ability to exercise, and will be associated 
with a rise in NT-proBNP).50
CONCLUSIONS
In this large population-based study, we have found 
several measures of end-organ damage/stress and 
systemic inflammation that are associated with sub-
sequent level and decline in physical capability. The 
associations with subsequent physical capability re-
mained even after adjustment for conventional di-
sease markers and cumulative adverse socioeconomic 
exposures. Novel associations between NT-proBNP and 
physical capability were consistent across several differ-
ent measures of capability and, as such, merit further 
replication. Elevation of NT-proBNP may identify those 
in midlife at risk of accelerated physical decline. These 
simple and relatively cheap blood-based measures—
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and in the case of NT-proBNP, widely available in auto-
mated assays—could be used for risk stratification to 
identify individuals at risk of poor physical capability for 
any future targeted interventions to improve capabil-
ity. Further research needs to untangle whether these 
associations reflect the biomarker being a good inte-
grated measure of cumulative exposures to relevant 
stressors or whether they point to or reflect additional 
pathways, such as central nervous system dysfunction, 
that may mediate the associations. Randomized trials 
that try to reduce the rate of decline in physical capa-
bility or delay incident disability could benefit from in-
cluding middle-aged adults and adding these biomark-
ers as intermediate outcomes.
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